The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms
Open accessAbstract
Background: Autoimmunity has been reported in patients with severe COVID-19. We investigated whether antinuclear/extractable-nuclear antibodies (ANAs) were present up to a year after infection, and if they were associated with the development of clinically relevant Post-Acute Sequalae of COVID-19 (PASC) symptoms. Methods: A rapid assessment line immunoassay was used to measure circulating levels of ANA/ENAs in 106 convalescent COVID-19 patients with varying acute phase severities at 3, 6, and 12 months post-recovery. Patient-reported fatigue, cough, and dyspnea were recorded at each timepoint. Multivariable logistic regression model and receiver-operating curves (ROC) were used to test the association of autoantibodies with patient-reported outcomes and pro-inflammatory cytokines. Results: Compared to age- and sex-matched healthy controls (n=22) and those who had other respiratory infections (n=34), patients with COVID-19 had higher detectable ANAs at 3 months post-recovery (p<0.001). The mean number of ANA autoreactivities per individual decreased from 3 to 12 months (3.99 to 1.55) with persistent positive titers associated with fatigue, dyspnea, and cough severity. Antibodies to U1-snRNP and anti-SS-B/La were both positively associated with persistent symptoms of fatigue (p<0.028, AUC=0.86) and dyspnea (p<0.003, AUC=0.81). Pro-inflammatory cytokines such as tumour necrosis factor alpha (TNFα) and C-reactive protein predicted the elevated ANAs at 12 months. TNFα, D-dimer, and IL-1β had the strongest association with symptoms at 12 months. Regression analysis showed TNFα predicted fatigue (β=4.65, p=0.004) and general symptomaticity (β=2.40, p=0.03) at 12 months. Interpretation: Persistently positive ANAs at 12 months post-COVID are associated with persisting symptoms and inflammation (TNFα) in a subset of COVID-19 survivors. This finding indicates the need for further investigation into the role of autoimmunity in PASC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nalbandian, A., Sehgal, K., Gupta, A., Madhavan, M. V., McGroder, C., Stevens, J. S., Cook, J. R., Nordvig, A. S., Shalev, D., Sehrawat, T. S., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01283-z · Cited by 4,862
More than 50 long-term effects of COVID-19: a systematic review and meta-analysis
Lopez-Leon, S., Wegman-Ostrosky, T., Perelman, C., Sepulveda, R., Rebolledo, P. A., Cuapio, A., & Villapol, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-95565-8 · Cited by 2,757
Autoantibodies against type I IFNs in patients with life-threatening COVID-19
Bastard, P., Rosen, L. B., Zhang, Q., Michailidis, E., Hoffmann, H.-H., Zhang, Y., Dorgham, K., Philippot, Q., Rosain, J., Béziat, V., et al. (2020) · Science · doi:10.1126/science.abd4585 · Cited by 2,662
An inflammatory cytokine signature predicts COVID-19 severity and survival
Del Valle, D. M., Kim-Schulze, S., Huang, H.-H., Beckmann, N. D., Nirenberg, S., Wang, B., Lavin, Y., Swartz, T. H., Madduri, D., Stock, A., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1051-9 · Cited by 2,605
SARS-CoV-2 is associated with changes in brain structure in UK Biobank
Douaud, G., Lee, S., Alfaro-Almagro, F., Arthofer, C., Wang, C., McCarthy, P., Lange, F., Andersson, J. L. R., Griffanti, L., Duff, E., et al. (2022) · Nature · doi:10.1038/s41586-022-04569-5 · Cited by 1,646
Multiple early factors anticipate post-acute COVID-19 sequelae
Su, Y., Yuan, D., Chen, D. G., Ng, R. H., Wang, K., Choi, J., Li, S., Hong, S., Zhang, R., Xie, J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.01.014 · Cited by 1,156
Cited by
Yin, K., Peluso, M. J., Luo, X., Thomas, R., Shin, M.-G., Neidleman, J., Andrew, A., Young, K. C., Ma, T., Hoh, R., et al. (2024) · Nature Immunology · doi:10.1038/s41590-023-01724-6 · Cited by 394
Altmann, D. M., Whettlock, E. M., Liu, S., Arachchillage, D. J., & Boyton, R. J. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00904-7 · Cited by 389
Mechanisms of long COVID and the path toward therapeutics
Peluso, M. J., & Deeks, S. G. (2024) · Cell · doi:10.1016/j.cell.2024.07.054 · Cited by 341
Komaroff, A. L., & Lipkin, W. I. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1187163 · Cited by 317
Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress
Gjølberg, T. T., Mester, S., Calamera, G., Telstad, J. S., Sandlie, I., & Andersen, J. T. (2025) · BioDrugs · doi:10.1007/s40259-025-00708-2 · Cited by 20
Metadata
- Authors
- Son, K., Jamil, R., Chowdhury, A., Mukherjee, M., Venegas, C., Miyasaki, K., Zhang, K., Patel, Z., Salter, B., Yuen, A. C. Y., Lau, K. S.-K., Cowbrough, B., Radford, K., Huang, C., Kjarsgaard, M., Dvorkin-Gheva, A., Smith, J., Li, Q.-Z., Waserman, S., Ryerson, C. J., Nair, P., Ho, T., Balakrishnan, N., Nazy, I., Bowdish, D. M., Svenningsen, S., Carlsten, C., & Mukherjee, M.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2022-09-22
- Volume
- 61
- Issue
- 1
- Pages
- 2200970
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W4296679855
- Cited by
- 211
- References
- 6
- FWCI
- 23.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms. https://app.cochat.ai/papers/10.1183/13993003.00970-2022
- The paper
- Son, K., Jamil, R., Chowdhury, A., Mukherjee, M., Venegas, C., Miyasaki, K., Zhang, K., Patel, Z., Salter, B., Yuen, A. C. Y., Lau, K. S.-K., Cowbrough, B., Radford, K., Huang, C., Kjarsgaard, M., Dvorkin-Gheva, A., Smith, J., Li, Q.-Z., Waserman, S., . . . Mukherjee, M. (2022). Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms. European Respiratory Journal. https://doi.org/10.1183/13993003.00970-2022
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.